Hem › Icke-småcellig lungcancer › Illinois › Joliet
Kliniska studier för Icke-småcellig lungcancer i Joliet, IL
12 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Joliet (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekryterarFas 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi bort
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi bort
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekryterarFas 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekryterarFas 3
- Hope and Healing Cancer Services, New Lenox · 6 mi bort
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekryterarFas 3
- Hope and Healing Cancer Services, New Lenox · 6 mi bort
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RekryterarFas 2
- Hope and Healing Clinical Research, New Lenox · 6 mi bort
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- University of Chicago, New Lenox · 6 mi bort
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekryterarFas 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekryterarFas 1
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi bort
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi bort
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekryterarFas 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi bort
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Joliet
- Lungcancer12 studier
- Blåscancer7 studier
- Metastaserande cancer7 studier
- Plattenepitelcancer i huvud och hals6 studier
- Prostatacancer5 studier
- Akut myeloid leukemi5 studier
- Hypofarynxcancer5 studier
- Struphuvudcancer5 studier
- Munhålecancer5 studier
- Bröstcancer4 studier
- Äggstockscancer4 studier
- Tjocktarmscancer4 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.